Fibromyalgia  ||| S:0 E:13 ||| NNP
in  ||| S:13 E:16 ||| IN
patients  ||| S:16 E:25 ||| NNS
with  ||| S:25 E:30 ||| IN
ankylosing  ||| S:30 E:41 ||| JJ
spondylitis ||| S:41 E:52 ||| NN
:  ||| S:52 E:54 ||| :
prevalence  ||| S:54 E:65 ||| NNS
and  ||| S:65 E:69 ||| CC
utility  ||| S:69 E:77 ||| NN
of  ||| S:77 E:80 ||| IN
the  ||| S:80 E:84 ||| DT
measures  ||| S:84 E:93 ||| NNS
of  ||| S:93 E:96 ||| IN
activity ||| S:96 E:104 ||| NN
,  ||| S:104 E:106 ||| ,
function  ||| S:106 E:115 ||| NN
and  ||| S:115 E:119 ||| CC
radiological  ||| S:119 E:132 ||| JJ
damage  ||| S:132 E:139 ||| NN
To  ||| S:139 E:142 ||| TO
determine  ||| S:142 E:152 ||| VB
the  ||| S:152 E:156 ||| DT
prevalence  ||| S:156 E:167 ||| NN
of  ||| S:167 E:170 ||| IN
fibromyalgia  ||| S:170 E:183 ||| NNS
( ||| S:183 E:184 ||| -LRB-
FM ||| S:184 E:186 ||| NNP
)  ||| S:186 E:188 ||| -RRB-
in  ||| S:188 E:191 ||| IN
ankylosing  ||| S:191 E:202 ||| JJ
spondylitis  ||| S:202 E:214 ||| NNS
( ||| S:214 E:215 ||| -LRB-
AS ||| S:215 E:217 ||| NNP
) ||| S:217 E:218 ||| -RRB-
.  ||| S:218 E:220 ||| .
To  ||| S:220 E:223 ||| TO
evaluate  ||| S:223 E:232 ||| VB
the  ||| S:232 E:236 ||| DT
effect  ||| S:236 E:243 ||| NN
of  ||| S:243 E:246 ||| IN
FM  ||| S:246 E:249 ||| NNP
on  ||| S:249 E:252 ||| IN
the  ||| S:252 E:256 ||| DT
measures  ||| S:256 E:265 ||| NNS
of  ||| S:265 E:268 ||| IN
activity  ||| S:268 E:277 ||| NN
in  ||| S:277 E:280 ||| IN
AS ||| S:280 E:282 ||| NNP
.  ||| S:282 E:284 ||| .
To  ||| S:284 E:287 ||| TO
analyse  ||| S:287 E:295 ||| VB
predictive  ||| S:295 E:306 ||| JJ
factors  ||| S:306 E:314 ||| NNS
in  ||| S:314 E:317 ||| IN
order  ||| S:317 E:323 ||| NN
to  ||| S:323 E:326 ||| TO
identify  ||| S:326 E:335 ||| VB
this  ||| S:335 E:340 ||| DT
group  ||| S:340 E:346 ||| NN
of  ||| S:346 E:349 ||| IN
patients ||| S:349 E:357 ||| NNS
.  ||| S:357 E:359 ||| .
A  ||| S:359 E:361 ||| DT
cross-sectional  ||| S:361 E:377 ||| JJ
study  ||| S:377 E:383 ||| NN
based  ||| S:383 E:389 ||| VBN
on  ||| S:389 E:392 ||| IN
462  ||| S:392 E:396 ||| CD
patients  ||| S:396 E:405 ||| NNS
with  ||| S:405 E:410 ||| IN
definite  ||| S:410 E:419 ||| JJ
ankylosing  ||| S:419 E:430 ||| NNS
spondylitis  ||| S:430 E:442 ||| VBP
included  ||| S:442 E:451 ||| VBN
in  ||| S:451 E:454 ||| IN
the  ||| S:454 E:458 ||| DT
REGISPONSER ||| S:458 E:469 ||| NNP
.  ||| S:469 E:471 ||| .
Sociodemographic  ||| S:471 E:488 ||| JJ
data ||| S:488 E:492 ||| NNS
,  ||| S:492 E:494 ||| ,
clinical  ||| S:494 E:503 ||| JJ
features ||| S:503 E:511 ||| NNS
,  ||| S:511 E:513 ||| ,
Bath  ||| S:513 E:518 ||| NNP
AS  ||| S:518 E:521 ||| NNP
disease  ||| S:521 E:529 ||| NN
activity  ||| S:529 E:538 ||| NN
index  ||| S:538 E:544 ||| NN
( ||| S:544 E:545 ||| -LRB-
BASDAI ||| S:545 E:551 ||| NNP
) ||| S:551 E:552 ||| -RRB-
,  ||| S:552 E:554 ||| ,
Bath  ||| S:554 E:559 ||| NNP
AS  ||| S:559 E:562 ||| NNP
functional  ||| S:562 E:573 ||| JJ
index  ||| S:573 E:579 ||| NN
( ||| S:579 E:580 ||| -LRB-
BASFI ||| S:580 E:585 ||| NNP
) ||| S:585 E:586 ||| -RRB-
,  ||| S:586 E:588 ||| ,
Bath  ||| S:588 E:593 ||| NNP
AS  ||| S:593 E:596 ||| NNP
radiology  ||| S:596 E:606 ||| JJ
index  ||| S:606 E:612 ||| NN
( ||| S:612 E:613 ||| -LRB-
BASRI ||| S:613 E:618 ||| NNP
) ||| S:618 E:619 ||| -RRB-
,  ||| S:619 E:621 ||| ,
Stoke  ||| S:621 E:627 ||| NNP
modified  ||| S:627 E:636 ||| JJ
index  ||| S:636 E:642 ||| NN
( ||| S:642 E:643 ||| -LRB-
Sasss-m ||| S:643 E:650 ||| NNP
) ||| S:650 E:651 ||| -RRB-
,  ||| S:651 E:653 ||| ,
laboratory  ||| S:653 E:664 ||| NN
data ||| S:664 E:668 ||| NNS
,  ||| S:668 E:670 ||| ,
Short-Format  ||| S:670 E:683 ||| JJ
12  ||| S:683 E:686 ||| CD
( ||| S:686 E:687 ||| -LRB-
SF-12 ||| S:687 E:692 ||| NNP
) ||| S:692 E:693 ||| -RRB-
,  ||| S:693 E:695 ||| ,
AS  ||| S:695 E:698 ||| IN
specific  ||| S:698 E:707 ||| JJ
quality  ||| S:707 E:715 ||| NN
of  ||| S:715 E:718 ||| IN
life  ||| S:718 E:723 ||| NN
( ||| S:723 E:724 ||| -LRB-
ASQoL ||| S:724 E:729 ||| NNP
) ||| S:729 E:730 ||| -RRB-
,  ||| S:730 E:732 ||| ,
Fibromyalgia  ||| S:732 E:745 ||| NNP
Impact  ||| S:745 E:752 ||| NNP
Questionnaire  ||| S:752 E:766 ||| NNP
( ||| S:766 E:767 ||| -LRB-
FIQ ||| S:767 E:770 ||| NNP
)  ||| S:770 E:772 ||| -RRB-
and  ||| S:772 E:776 ||| CC
treatments  ||| S:776 E:787 ||| NNS
used  ||| S:787 E:792 ||| VBN
were  ||| S:792 E:797 ||| VBD
all  ||| S:797 E:801 ||| DT
documented ||| S:801 E:811 ||| NN
.  ||| S:811 E:813 ||| .
To  ||| S:813 E:816 ||| TO
diagnose  ||| S:816 E:825 ||| VB
FM ||| S:825 E:827 ||| NNP
,  ||| S:827 E:829 ||| ,
the  ||| S:829 E:833 ||| DT
ACR  ||| S:833 E:837 ||| NNP
1990  ||| S:837 E:842 ||| CD
criteria  ||| S:842 E:851 ||| NNS
had  ||| S:851 E:855 ||| VBD
to  ||| S:855 E:858 ||| TO
be  ||| S:858 E:861 ||| VB
fulfilled ||| S:861 E:870 ||| VBN
.  ||| S:870 E:872 ||| .
All  ||| S:872 E:876 ||| DT
statistical  ||| S:876 E:888 ||| JJ
tests  ||| S:888 E:894 ||| NNS
were  ||| S:894 E:899 ||| VBD
performed  ||| S:899 E:909 ||| VBN
using  ||| S:909 E:915 ||| VBG
STATA ||| S:915 E:920 ||| NNP
.  ||| S:920 E:922 ||| .
The  ||| S:922 E:926 ||| DT
prevalence  ||| S:926 E:937 ||| NN
of  ||| S:937 E:940 ||| IN
fibromyalgia  ||| S:940 E:953 ||| NN
in  ||| S:953 E:956 ||| IN
all  ||| S:956 E:960 ||| DT
AS  ||| S:960 E:963 ||| NNP
was  ||| S:963 E:967 ||| VBD
4.11 ||| S:967 E:971 ||| CD
% ||| S:971 E:972 ||| NN
.  ||| S:972 E:974 ||| .
Among  ||| S:974 E:980 ||| IN
the  ||| S:980 E:984 ||| DT
women  ||| S:984 E:990 ||| NNS
with  ||| S:990 E:995 ||| IN
AS ||| S:995 E:997 ||| NNP
,  ||| S:997 E:999 ||| ,
the  ||| S:999 E:1003 ||| DT
prevalence  ||| S:1003 E:1014 ||| NN
of  ||| S:1014 E:1017 ||| IN
FM  ||| S:1017 E:1020 ||| NNP
increased  ||| S:1020 E:1030 ||| VBD
to  ||| S:1030 E:1033 ||| TO
10.83 ||| S:1033 E:1038 ||| CD
% ||| S:1038 E:1039 ||| NN
.  ||| S:1039 E:1041 ||| .
The  ||| S:1041 E:1045 ||| DT
BASDAI ||| S:1045 E:1051 ||| NNP
,  ||| S:1051 E:1053 ||| ,
BASFI  ||| S:1053 E:1059 ||| NNP
and  ||| S:1059 E:1063 ||| CC
total  ||| S:1063 E:1069 ||| JJ
BASRI  ||| S:1069 E:1075 ||| NNP
were  ||| S:1075 E:1080 ||| VBD
strongly  ||| S:1080 E:1089 ||| RB
influenced  ||| S:1089 E:1100 ||| VBN
by  ||| S:1100 E:1103 ||| IN
the  ||| S:1103 E:1107 ||| DT
presence  ||| S:1107 E:1116 ||| NN
of  ||| S:1116 E:1119 ||| IN
FM ||| S:1119 E:1121 ||| NNP
.  ||| S:1121 E:1123 ||| .
The  ||| S:1123 E:1127 ||| DT
inverse  ||| S:1127 E:1135 ||| JJ
relationship  ||| S:1135 E:1148 ||| NN
between  ||| S:1148 E:1156 ||| IN
BASDAI  ||| S:1156 E:1163 ||| NNP
or  ||| S:1163 E:1166 ||| CC
BASFI  ||| S:1166 E:1172 ||| NNP
and  ||| S:1172 E:1176 ||| CC
total  ||| S:1176 E:1182 ||| JJ
BASRI  ||| S:1182 E:1188 ||| NNP
was  ||| S:1188 E:1192 ||| VBD
taken  ||| S:1192 E:1198 ||| VBN
to  ||| S:1198 E:1201 ||| TO
generate  ||| S:1201 E:1210 ||| VB
a  ||| S:1210 E:1212 ||| DT
ratio ||| S:1212 E:1217 ||| NN
.  ||| S:1217 E:1219 ||| .
Accordingly ||| S:1219 E:1230 ||| RB
,  ||| S:1230 E:1232 ||| ,
if  ||| S:1232 E:1235 ||| IN
the  ||| S:1235 E:1239 ||| DT
patient  ||| S:1239 E:1247 ||| NN
presented  ||| S:1247 E:1257 ||| VBD
BASDAI ||| S:1257 E:1263 ||| NNP
/ ||| S:1263 E:1264 ||| NNP
BASRI  ||| S:1264 E:1270 ||| NNP
≥1.5  ||| S:1270 E:1275 ||| NNP
or  ||| S:1275 E:1278 ||| CC
BASFI ||| S:1278 E:1283 ||| NNP
/ ||| S:1283 E:1284 ||| NNP
BASRI  ||| S:1284 E:1290 ||| NNP
≥1.08 ||| S:1290 E:1295 ||| NNP
,  ||| S:1295 E:1297 ||| ,
the  ||| S:1297 E:1301 ||| DT
probability  ||| S:1301 E:1313 ||| NN
of  ||| S:1313 E:1316 ||| IN
having  ||| S:1316 E:1323 ||| VBG
FM  ||| S:1323 E:1326 ||| NNP
was  ||| S:1326 E:1330 ||| VBD
very  ||| S:1330 E:1335 ||| RB
high ||| S:1335 E:1339 ||| JJ
.  ||| S:1339 E:1341 ||| .
There  ||| S:1341 E:1347 ||| EX
is  ||| S:1347 E:1350 ||| VBZ
an  ||| S:1350 E:1353 ||| DT
increased  ||| S:1353 E:1363 ||| JJ
risk  ||| S:1363 E:1368 ||| NN
of  ||| S:1368 E:1371 ||| IN
FM  ||| S:1371 E:1374 ||| NNP
in  ||| S:1374 E:1377 ||| IN
females  ||| S:1377 E:1385 ||| NNS
with  ||| S:1385 E:1390 ||| IN
AS ||| S:1390 E:1392 ||| NNP
.  ||| S:1392 E:1394 ||| .
The  ||| S:1394 E:1398 ||| DT
fact  ||| S:1398 E:1403 ||| NN
of  ||| S:1403 E:1406 ||| IN
having  ||| S:1406 E:1413 ||| VBG
FM  ||| S:1413 E:1416 ||| NNP
distorts  ||| S:1416 E:1425 ||| VBZ
the  ||| S:1425 E:1429 ||| DT
measures  ||| S:1429 E:1438 ||| NNS
of  ||| S:1438 E:1441 ||| IN
activity  ||| S:1441 E:1450 ||| NN
and  ||| S:1450 E:1454 ||| CC
functional  ||| S:1454 E:1465 ||| JJ
damage  ||| S:1465 E:1472 ||| NN
of  ||| S:1472 E:1475 ||| IN
AS ||| S:1475 E:1477 ||| NNP
.  ||| S:1477 E:1479 ||| .
As  ||| S:1479 E:1482 ||| IN
a  ||| S:1482 E:1484 ||| DT
result ||| S:1484 E:1490 ||| NN
,  ||| S:1490 E:1492 ||| ,
it  ||| S:1492 E:1495 ||| PRP
is  ||| S:1495 E:1498 ||| VBZ
possible  ||| S:1498 E:1507 ||| JJ
that  ||| S:1507 E:1512 ||| IN
some  ||| S:1512 E:1517 ||| DT
patients  ||| S:1517 E:1526 ||| NNS
with  ||| S:1526 E:1531 ||| IN
AS  ||| S:1531 E:1534 ||| NNP
and  ||| S:1534 E:1538 ||| CC
FM  ||| S:1538 E:1541 ||| NNP
are  ||| S:1541 E:1545 ||| VBP
being  ||| S:1545 E:1551 ||| VBG
overtreated ||| S:1551 E:1562 ||| NNS
.  ||| S:1562 E:1564 ||| .
The  ||| S:1564 E:1568 ||| DT
BASDAI ||| S:1568 E:1574 ||| NNP
/ ||| S:1574 E:1575 ||| NNP
BASRI  ||| S:1575 E:1581 ||| NNP
and  ||| S:1581 E:1585 ||| CC
BASFI ||| S:1585 E:1590 ||| NNP
/ ||| S:1590 E:1591 ||| NNP
BASRI  ||| S:1591 E:1597 ||| NNP
ratios  ||| S:1597 E:1604 ||| NNS
are  ||| S:1604 E:1608 ||| VBP
very  ||| S:1608 E:1613 ||| RB
useful  ||| S:1613 E:1620 ||| JJ
to  ||| S:1620 E:1623 ||| TO
identify  ||| S:1623 E:1632 ||| VB
these  ||| S:1632 E:1638 ||| DT
patients ||| S:1638 E:1646 ||| NNS
.  ||| S:1646 E:1648 ||| .
